Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function

Reviews of Infectious Diseases

Volumn 10, Issue , 1988, Pages S507-S514

  Sommadossi, Jean Pierre ^a,b,c   Bevan, Rae ^a,b   Ling, Teck ^a,b   Lee, Frank ^a,b   Mastre, Barbara ^a,b   Chaplin, Melvin D ^a,b   Nerenberg, Clinton ^a,b   Koretz, Stuart ^a,b   Buhles, William C ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c University Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR;

ADULT; ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MALE; METABOLISM;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMAN; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGE; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024041595     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/10.Supplement_3.S507     Document Type: Article

References (21)

1. Lerner CW, Tapper ML. Opportunistic infection complicating acquired immune deficiency syndrome; clinical features of 25 cases. Medicine (Baltimore) 1984;63:155-64.
2. Meyers JD, Spencer HC Jr, Watts JC, Gregg MB, Stewart JA, Troupin RH, Thomas EP. Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 1975;82:181-8.
3. Cheng Y-C, Huang E-S, Lin J-C, Mar E-C, Pagano JS, Dutschman GE, Grill SP. Unique spectrum of activity of 9-[(l, 3-dihydroxy-2-propoxy)methyl]guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983;80: 2767-70.
4. Field AK, Davies ME, Dewitt C, Perry HC, Liou R, Germerhausen J, Karkas JD, Ashton WT, Johnson DBR, Tolman RL. 9-([2-hydroxy-l-(hydroxymethyl)ethoxy]methyl) guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983;80:4139-43.
5. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(l, 3-di-hydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;152: 833-4.
6. Boehme RE. Phosphorylation of the antiviral precursor 9-(l, 3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isoenzymes. J Biol Chem 1984;259: 12346-9.
7. Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, Nelson DJ. Metabolic activation of the nucleoside analog 9-([2-hydroxy-l-(hydroxmethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82:2473-7.
8. Cheng Y-C, Grill SP, Dutschman GE, Frank KB, Chiou J-F, S514 Bastow KF, Nakayama K. Effects of 9-(l, 3-dihydroxy-2-propoxymethyl)guanine, a new antiherpesvirus compound, on synthesis of macromolecules in herpes simplex virus-infected cells. Antimicrob Agents Chemother 1984; 26: 283-8.
9. Smee DF, Boehme R, Chernow M, Binko BP, Matthews TR. Intracellular metabolism and enzymatic phosphorylation of 9-(l, 3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Bio-chem Pharmacol 1985;34:1049-56.
10. Bach MC, Bagwell SP, Knapp NP, Davis KM, Hedstrom PS. 9-(l, 3-dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:381-2.
11. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(l, 3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-5.
12. Felsenstein D, D’Amico DJ, Hirsch MS, Neumeyer DA, Cederberg DM, De Miranda P, Schooley RT. Treatment of cytomegalovirus retinitis with 9-([2-hydroxy-l-(hydroxymethyl) ethoxy]methyl)guanine. Ann Intern Med 1985;103:377-80.
13. Masur H, Lane HC, Palestine A, Smith PD, Manischewitz J, Stevens G, Fujikawa L, Macher AM, Nussenblatt R, Baird B, Megill M, Wittek A, Quinnan GV, Parrillo JE, Rook AH, Eron LJ, Poretz DM, Goldenberg RI, Fauci AS, Gelmann EP. Effect of 9-(l, 3-dihydroxy-2-propoxy-methyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986;104:41-4.
14. Palestine AG, Stevens G Jr, Lane HC, Masur H, Fujikawa LS, Nussenblatt RB, Rook AH, Manischewitz J, Baird B, Megill M, Quinnan G, Gelmann E, Fauci AS. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986;101:95-101.
15. Buhles WC, Mastre BJ, Tinker AJ, Strand V, Koretz SH, the Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life-or sight-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients. Rev Infect Dis 1988;10(Suppl 3): S495-506.
16. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-35.
17. Sommadossi JP, Bevan R. High performance liquid chromatographic method for the determination of 9-(l, 3-dihydroxy-2-propoxymethyl)guanine in human plasma. J Chromatogr 1987;414:429-33.
18. Nerenberg C, McClung S, Martin J, Fass M, LaFargue J, Kushinsky S. A radioimmunoassay procedure for the determination of the antiviral nucleoside DHPG (9-[l, 3-di-hydroxy-2-propoxy)-methyl]guanine) in plasma or serum. Pharm Res 1986;3:112-5.
19. Fletcher C, Sawchuk R, Chinnock B, De Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986;40:281-6.
20. Shepp DH, Dandliker PS, De Miranda P, Burnette TC, Cederberg DM, Kirk LE, Meyers JD. Activity of 9-(2-hydroxy-l-(hydroxymethyl)ethoxymethyl)guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103:368-73.
21. Visor GC, Lin L-H, Jackson SE, Winterle JS, Lee G, Kenley RA. Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1986;43:2810-12.